Payment overview · 2025
General Payments
$91.79
6 reported records · 3 companies
Healthcare provider profile · identity verified
John Scribner, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SALEM, AR · NPI 1972672897
Verified facts
What the public records show
CMS Open Payments records show John Scribner, M.D. received $91.79 in general payments during 2025 across 6 reported records.
PFIZER INC. accounted for 65.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 539 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $59.86 | 65.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.63 | 18.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.30 | 16.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $91.79 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $59.86 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $59.86 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 149 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
156 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
149 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
38 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
539 | 65 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1059 | 207 |
| Levothyroxine Sodium | Levothyroxine Sodium | 900 | 165 |
| Pantoprazole Sodium | Pantoprazole Sodium | 799 | 184 |
| Furosemide | Furosemide | 718 | 153 |
| Metoprolol Tartrate | Metoprolol Tartrate | 684 | 124 |
| Potassium Chloride | Potassium Chloride | 644 | 129 |
| Metformin Hcl | Metformin Hcl | 550 | 110 |
| Eliquis | Apixaban | 539 | 65 |
| Lisinopril | Lisinopril | 527 | 120 |
| Tamsulosin Hcl | Tamsulosin Hcl | 519 | 112 |
| Gabapentin | Gabapentin | 488 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 471 | 106 |
| Clopidogrel | Clopidogrel Bisulfate | 400 | 84 |
| Carvedilol | Carvedilol | 397 | 75 |
| Losartan Potassium | Losartan Potassium | 391 | 95 |
| Sertraline Hcl | Sertraline Hcl | 352 | 72 |
| Omeprazole | Omeprazole | 319 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 318 | 70 |
| Montelukast Sodium | Montelukast Sodium | 317 | 68 |
| Meloxicam | Meloxicam | 313 | 71 |
| Tramadol Hcl | Tramadol Hcl | 313 | 85 |
| Trazodone Hcl | Trazodone Hcl | 311 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 241 | 82 |
| Xarelto | Rivaroxaban | 235 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 232 | 53 |
| Citalopram Hbr | Citalopram Hydrobromide | 215 | 48 |
| Mirtazapine | Mirtazapine | 211 | 53 |
| Memantine Hcl | Memantine Hcl | 207 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 206 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 189 | 50 |
| Spironolactone | Spironolactone | 187 | 40 |
| Clonazepam | Clonazepam | 184 | 46 |
| Lorazepam | Lorazepam | 181 | 44 |
| Baclofen | Baclofen | 177 | 52 |
| Pioglitazone Hcl | Pioglitazone Hcl | 177 | 38 |
| Glipizide | Glipizide | 165 | 31 |
| Azithromycin | Azithromycin | 164 | 121 |
| Allopurinol | Allopurinol | 157 | 32 |
| Atenolol | Atenolol | 157 | 28 |
| Donepezil Hcl | Donepezil Hcl | 156 | 25 |
| Jardiance | Empagliflozin | 156 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 154 | 42 |
| Levetiracetam | Levetiracetam | 152 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 150 | 29 |
| Simvastatin | Simvastatin | 150 | 33 |
| Ozempic | Semaglutide | 149 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 146 | 33 |
| Buspirone Hcl | Buspirone Hcl | 144 | 34 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 144 | 29 |
| Bumetanide | Bumetanide | 143 | 32 |
| Farxiga | Dapagliflozin Propanediol | 141 | 20 |
| Prednisone | Prednisone | 138 | 48 |
| Doxycycline Hyclate | Doxycycline Hyclate | 137 | 94 |
| Fluticasone Propionate | Fluticasone Propionate | 130 | 51 |
| Fluoxetine Hcl | Fluoxetine Hcl | 129 | 29 |
| Lamotrigine | Lamotrigine | 125 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 121 | 23 |
| Celecoxib | Celecoxib | 120 | 29 |
| Warfarin Sodium | Warfarin Sodium | 120 | 22 |
| Finasteride | Finasteride | 118 | 29 |
| Topiramate | Topiramate | 118 | 17 |
| Januvia | Sitagliptin Phosphate | 114 | 12 |
| Bupropion Xl | Bupropion Hcl | 110 | 24 |
| Divalproex Sodium | Divalproex Sodium | 109 | 26 |
| Albuterol Sulfate | Albuterol Sulfate | 102 | 47 |
| Latanoprost | Latanoprost | 101 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 21 |
| Alprazolam | Alprazolam | 96 | 19 |
| Famotidine | Famotidine | 96 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 18 |
| Pregabalin | Pregabalin | 95 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 92 | 33 |
| Aripiprazole | Aripiprazole | 91 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 90 | 17 |
| Nystatin | Nystatin | 90 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 88 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 87 | 17 |
| Digoxin | Digoxin | 83 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 83 | 17 |
| Ezetimibe | Ezetimibe | 82 | 19 |
| Linzess | Linaclotide | 82 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 82 | 28 |
| Ondansetron Odt | Ondansetron | 81 | 45 |
| Nifedipine Er | Nifedipine | 79 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 77 | 59 |
| Tresiba Flextouch U-200 | Insulin Degludec | 77 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 76 | 54 |
| Nortriptyline Hcl | Nortriptyline Hcl | 73 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 17 |
| Sucralfate | Sucralfate | 71 | 17 |
| Myrbetriq | Mirabegron | 69 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 68 | 12 |
| Lactulose | Lactulose | 68 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 66 | 56 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 65 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 16 |
| Nitroglycerin | Nitroglycerin | 64 | 36 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 64 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 18 |
| Tresiba Flextouch U-100 | Insulin Degludec | 60 | 12 |
| Glipizide Er | Glipizide | 59 | 13 |
| Methylprednisolone | Methylprednisolone | 59 | 49 |
| Cefdinir | Cefdinir | 58 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 38 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 55 | suppressed |
| Entresto | Sacubitril/Valsartan | 55 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 54 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 53 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 53 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 51 | 13 |
| Lidocaine Hcl | Lidocaine Hcl | 51 | 41 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 50 | 17 |
| Methocarbamol | Methocarbamol | 50 | 12 |
| Gemfibrozil | Gemfibrozil | 49 | suppressed |
| Glimepiride | Glimepiride | 49 | suppressed |
| Insulin Aspart | Insulin Aspart | 48 | 19 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 48 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 11 |
| Alendronate Sodium | Alendronate Sodium | 47 | 11 |
| Ceftriaxone | Ceftriaxone Sodium | 47 | 37 |
| Clonidine Hcl | Clonidine Hcl | 47 | 19 |
| Fentanyl | Fentanyl | 46 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 46 | 23 |
| Terazosin Hcl | Terazosin Hcl | 45 | suppressed |
| Fluconazole | Fluconazole | 44 | 28 |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 44 | 17 |
| Insulin Lispro | Insulin Lispro | 43 | suppressed |
| Ketoconazole | Ketoconazole | 43 | 23 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 42 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 41 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 40 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 40 | suppressed |
| Estradiol | Estradiol | 39 | 15 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 38 | 38 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 38 | suppressed |
| Olanzapine | Olanzapine | 38 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 37 | suppressed |
| Risperidone | Risperidone | 37 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 35 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | 14 |
| Roflumilast | Roflumilast | 35 | suppressed |
| Naproxen | Naproxen | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Primidone | Primidone | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 30 |
| Benztropine Mesylate | Benztropine Mesylate | 32 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 32 | suppressed |
| Novolog | Insulin Aspart | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Ramipril | Ramipril | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 31 | suppressed |
| Cephalexin | Cephalexin | 31 | 26 |
| Metolazone | Metolazone | 31 | suppressed |
| Trimethoprim | Trimethoprim | 31 | suppressed |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 30 | 11 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 30 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 25 |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 28 | suppressed |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 28 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 28 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | 11 |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Calcitriol | Calcitriol | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 15 |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Nystop | Nystatin | 25 | 17 |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 21 |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 24 | 11 |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Sotalol | Sotalol Hcl | 24 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 24 | suppressed |
| Timolol Maleate | Timolol Maleate | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 23 | suppressed |
| Novolin R | Insulin Regular, Human | 23 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Ertapenem | Ertapenem Sodium | 21 | 17 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 20 | suppressed |
| Constulose | Lactulose | 20 | suppressed |
| Levemir | Insulin Detemir | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Paliperidone Er | Paliperidone | 19 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 19 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Fluocinonide | Fluocinonide | 18 | 11 |
| Hydroxyurea | Hydroxyurea | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 17 |
| Silodosin | Silodosin | 18 | suppressed |
| Tacrolimus | Tacrolimus | 18 | 12 |
| Valacyclovir | Valacyclovir Hcl | 18 | 13 |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 17 | 11 |
| Metronidazole | Metronidazole | 17 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 17 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 17 | 12 |
| Gemtesa | Vibegron | 16 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 16 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 15 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 15 | 12 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 14 | suppressed |
| Invokamet | Canagliflozin/Metformin Hcl | 14 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Tresiba | Insulin Degludec | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Darunavir | Darunavir | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Edurant | Rilpivirine Hcl | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ritonavir | Ritonavir | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Dofetilide | Dofetilide | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 11 | suppressed |
| Voquezna | Vonoprazan Fumarate | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $91.79 · 6 records | PFIZER INC. | MOUNJARO, NURTEC ODT, Ozempic, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error